Home»News & Opinion»New CDK4/6 Inhibitor Gets FDA Breakthrough Therapy Designation
News & Opinion
New CDK4/6 Inhibitor Gets FDA Breakthrough Therapy Designation
Ribociclib (LEE011) shows promise as first line of treatment for postmenopausal women with metastatic breast cancer that is hormone receptor-positive and HER2-negative